• YPL-001 is a natural product developed by Yungjin pharm for COPD treatment. It is the 1st Koran natural products with phase I IND approved by FDA and has been government funded project since 2011. Phase IIa is undergoing in 4 USA hospitals now and we are looking for licensing out partners or co-development partner after phase IIa.

[Unmet Medical Need & Target Patients]

Unmet Medical Needs

• Efficacy

- The primary unmet medical need of COPD is to find a treatment preventing the disease progression from stage 2 or 3 to stage 3or 4

• Steroid sensitivity

- COPD patients have a tendency of reduced responsiveness to steroids as their disease progresses. So symptoms get worse even using steroids especially for stage 3 or 4 patients. Thus, to reduce corticosteroid resistance in patients is important in acute or frequent COPD exacerbations.

• Safety

- COPD requires long-term treatment. Most of existing treatments for COPD have safety issues. Development of product with less side effects is needed. •

• Formulation

- Most COPD drugs are inhalant type which need patient education for usage. Oral dosage form is easy and convenient for dosing, usually cheaper than device type drug which is helpful especially in underdeveloped country.

[Target patients]

• COPD patients are classified based on their degree of severity - Mild (Stage 1), Moderate (Stage 2), Severe (Stage 3), Very severe (Stage 4). The ultimate and primary goal of treatments is to prevent exacerbation of COPD. For such purpose, long term safety and prevention the development of resistance should be secured. None of the existing

drugs have been proven to stop the disease progression from Stage 1 or 2 to Stage 3 or 4. YPL-001 is for stage 2 or 3 patients to prevent COPD exacerbation.

[Status]

• Yungjin has completed Phase 1a (Single Ascending Dose Study) and 1b study (Multiple Ascending Dose Study). The IND and IRB have been done for Phase IIa and currently patients recruiting are ongoing.